NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free LTRN Stock Alerts $6.81 +0.33 (+5.09%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$6.34▼$7.0150-Day Range$4.15▼$10.6552-Week Range$2.38▼$11.99Volume174,401 shsAverage Volume242,362 shsMarket Capitalization$73.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lantern Pharma alerts: Email Address Lantern Pharma MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.27Based on 4 Articles This WeekInsider TradingSelling Shares$360,340 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.02) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.10 out of 5 starsMedical Sector908th out of 915 stocksPharmaceutical Preparations Industry423rd out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lantern Pharma.Read more about Lantern Pharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.33% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently increased by 18.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LTRN. Previous Next 1.5 News and Social Media Coverage News SentimentLantern Pharma has a news sentiment score of -0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lantern Pharma this week, compared to 1 article on an average week.Search Interest23 people have searched for LTRN on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $360,340.00 in company stock.Percentage Held by InsidersOnly 6.92% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lantern Pharma are expected to grow in the coming year, from ($2.02) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Lantern Pharma Stock (NASDAQ:LTRN)Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc.was incorporated in 2013 and is headquartered in Dallas, Texas.Read More LTRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LTRN Stock News HeadlinesMay 9, 2024 | businesswire.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | americanbankingnews.comLantern Pharma (LTRN) Scheduled to Post Earnings on ThursdayMay 10, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 6, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 2, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETMay 1, 2024 | investorplace.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireApril 25, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 24, 2024 | finance.yahoo.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentMay 10, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…April 24, 2024 | businesswire.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 22, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 17, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN)April 13, 2024 | morningstar.comLantern Pharma Inc Ordinary SharesApril 10, 2024 | investing.comLantern Pharma Inc (LTRN)March 20, 2024 | seekingalpha.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | msn.comLTRN: 2023 ResultsMarch 19, 2024 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)March 19, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | investorplace.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023March 18, 2024 | benzinga.comRecap: Lantern Pharma Q4 EarningsMarch 18, 2024 | finance.yahoo.comLantern Pharma Inc Reports Progress and Financials for FY 2023March 18, 2024 | businesswire.comLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsMarch 16, 2024 | marketwatch.comLantern Pharma Up 20% After Dosing Initiated in Trial for Cancer Drug Developed with AIMarch 16, 2024 | finance.yahoo.comLTRN May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comLTRN Apr 2024 12.500 callMarch 15, 2024 | benzinga.comLantern Pharma Earnings PreviewMarch 15, 2024 | finance.yahoo.comLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284See More Headlines Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees21Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.11% Return on Assets-32.19% Debt Debt-to-Equity RatioN/A Current Ratio16.18 Quick Ratio16.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book1.81Miscellaneous Outstanding Shares10,760,000Free Float10,014,000Market Cap$73.28 million OptionableOptionable Beta1.57 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Panna Sharma PH.D. (Age 53)President, CEO & Director Comp: $633.25kMr. David R. Margrave (Age 63)CFO & Secretary Comp: $394.36kDr. Kishor Gopaldas Bhatia Ph.D. (Age 69)Chief Scientific Officer & Scientific Consultant Comp: $184.33kNicole LeberInvestor Relations Associate, Finance & Administrative CoordinatorDr. Peter L. Nara D.V.M.M.S., Ph.D., Co-Founder & AdvisorMr. Ernest Kitt B.S.M.S, Head of Clinical OperationsMore ExecutivesKey CompetitorsAssembly BiosciencesNASDAQ:ASMBLandos BiopharmaNASDAQ:LABPJourney MedicalNASDAQ:DERMSCYNEXISNASDAQ:SCYXViveon Health AcquisitionNYSE:VHAQView All CompetitorsInsiders & InstitutionsPathway Financial Advisors LLCSold 3,500 shares on 4/10/2024Ownership: 0.233%Aaron G.L. FletcherSold 74,297 sharesTotal: $360,340.45 ($4.85/share)Redmond Asset Management LLCSold 5,844 shares on 2/12/2024Ownership: 0.374%Aaron G.L. FletcherSold 58,889 sharesTotal: $247,333.80 ($4.20/share)Leslie W KreisSold 145,348 sharesTotal: $499,997.12 ($3.44/share)View All Insider TransactionsView All Institutional Transactions LTRN Stock Analysis - Frequently Asked Questions Should I buy or sell Lantern Pharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares. View LTRN analyst ratings or view top-rated stocks. How have LTRN shares performed in 2024? Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN shares have increased by 59.1% and is now trading at $6.81. View the best growth stocks for 2024 here. Are investors shorting Lantern Pharma? Lantern Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 420,900 shares, an increase of 191.1% from the March 15th total of 144,600 shares. Based on an average daily trading volume, of 276,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 5.3% of the company's stock are sold short. View Lantern Pharma's Short Interest. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. What ETF holds Lantern Pharma's stock? Horizon Kinetics Medical ETF holds 28,791 shares of LTRN stock, representing 1.00% of its portfolio. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK). When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. Who are Lantern Pharma's major shareholders? Lantern Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Pathway Financial Advisors LLC (0.23%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis. View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LTRN) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
